Pharmaceuticals & Biotech Italian Community

Recordati’s rare-disease drugs are getting a bigger role, helped by an aging population and expanded use of a key treatment for a hard-to-diagnose hormone condition. The catch is that pushing into broader patient groups requires heavy spending and changing how patients get referred, which could slow progress and squeeze profits in the near term.Read more

Recordati leans harder into rare-disease medicines, with one key treatment expanding into a much larger, often missed patient group and potentially reshaping the company’s growth outlook. The big question is whether doctors adopt it fast enough—and whether currency swings, pricing pressure, and regulatory setbacks get in the way.Read more

Philogen is nearing key decision points for its cancer and inflammatory disease treatments, and success could shift it from one-off partner payments to steadier product sales. But the business still depends heavily on approvals and partners, so delays or weak launches could quickly change the story.Read more

Recordati is leaning harder into rare-disease medicines and pushing further into new countries, which could make its growth less dependent on any one product or region. The catch is that this plan needs heavy spending and faces currency swings and tougher rules in the US—risks that could squeeze profits if new launches disappoint.Read more

Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?Read more